|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 322.11 USD | +0.26% |
|
+1.02% | -19.00% |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Discovery, Development, Manufacturing and Commercialization of Rnai Therapeutics | 844M | 1.04B | 1.83B | 2.25B | 3.71B | |||||
Total Assets | 3.64B | 3.55B | 3.83B | 4.24B | 4.97B | |||||
Interest Expense | -143M | -156M | -121M | -142M | -253M | |||||
Income Tax Expense | 680K | 4.16M | 6.72M | -99.22M | 9.4M | |||||
CAPEX | -76.37M | -72.06M | -62.21M | -34.28M | -58.7M | |||||
EBT | -852M | -1.13B | -434M | -377M | 323M | |||||
D&A | 89.69M | 85.55M | 97.03M | 56.67M | 55.66M | |||||
Operating Income | -709M | -785M | -282M | -177M | 502M | |||||
Net Income | -853M | -1.13B | -440M | -278M | 314M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | 325M | 473M | 689M | 934M | 2.07B | |||||
Income Tax Expense | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - | |||||
CAPEX | - | - | - | - | - | |||||
Net Income | - | - | - | - | - | |||||
EBT | - | - | - | - | - | |||||
Operating Income | - | - | - | - | - | |||||
Europe | 260M | 315M | 399M | 516M | 651M | |||||
Rest of World | 77.03M | 107M | 153M | 196M | 268M |
- Stock Market
- Equities
- ALNY Stock
- Financials Alnylam Pharmaceuticals, Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition